We are pleased to share that APACMed has published a joint intelligence piece by RegASK‘s Patricia Teysseyre, examining how regulators across Asia-Pacific are adopting AI internally, and what that means for MedTech teams.
When Regulators Use AI: What It Means for MedTech Teams looks at how regulators are using AI to screen submissions, review safety data, and speed decisions. It maps where key authorities stand today, from Singapore’s HSA risk-classification tool to Japan’s PMDA AI assistant and China’s NMPA query tool.
The article also examines where the two threads meet: as regulators use AI on the review side, they are adapting the frameworks that govern AI-enabled devices. It sets out the operational risks to watch, from model revalidation to human oversight, and the concrete steps teams can take now.
As AI becomes part of how regulators work, readiness comes down to structured, machine-readable, traceable evidence and defensible AI governance, across markets and on tighter timelines. Regulatory teams use RegASK to track these changes, assess the impact on a portfolio, and act on them early.
